1832 Asset Management L.P. Bei Gene, Ltd. Transaction History

1832 Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $93,128 - $170,140	742 Added 1279.31%	800 $175,000
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $7,644 - $11,729	58 New	58 $8,000
Q4 2021 Feb 15, 2022	SELL	$248.56 - $389.34 $7.66 Million - $12 Million	-30,800 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $499,200 - $806,280	-2,000 Reduced 6.1%	30,800 $11.2 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $731,875 - $917,525	2,500 Added 8.25%	32,800 $11.7 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $1.04 Million - $1.53 Million	4,000 Added 15.21%	30,300 $10.1 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $5.82 Million - $8.33 Million	26,300 New	26,300 $6.73 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.